The Atopic Dermatitis Countdown: Ready, Set, Go!

The goal of this activity is to improve the identification and treatment of patients who are candidates for systemic or biologic agents for atopic dermatitis, including incorporation of new therapies.
 
Educational Partner: Medscape, LLC

Medium: Online Module

Commercial Support: Support for this activity has been provided through and independent educational grant from LEO Pharma A/S and LEO Pharma Inc.

Target Audience

This activity is intended for dermatologists, allergists/immunologists, nurse practitioners, and physician assistants who practice in dermatology or allergy and other clinicians who manage patients with atopic dermatitis.

Learning Objectives

After completing this activity, participants will be able to:

  • Have increased knowledge regarding the
    • Burden of atopic dermatitis;
    • Role of interleukin (IL)-13 in the pathophysiology of atopic dermatitis;
    • Current evidence for new and emerging biologic agents for the treatment of atopic dermatitis.
Additional information
ACGME/ABMS Core Competencies: 
Medical Knowledge
For more information, please contact:
CME Coordinator Contact Name: 
Medscape
CME Coordinator Contact Email: 
Summary
Available credit: 
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
Activity opens: 
04/27/2022
Activity expires: 
04/27/2023
FACULTY
  Peter Lio, MD
  Clinical Assistant Professor of Dermatology and Pediatrics
  Feinberg School of Medicine
  Northwestern University
  Director
  Chicago Integrative Eczema Center
                         Chicago, Illinois
 
  Andrew Blauvelt, MD, MBA
  President
  Oregon Medical Research Center
  Portland, Oregon
 
PEER REVIEWER
  Angad Chadha, MD
  Assistant Professor
  Section of Dermatology
  The University of Chicago Medicine
  Chicago, IL

 

Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.

Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University Of Chicago Pritzker School Of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Other Healthcare Professions Credit
Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
REGISTRATION: To view this activity, you will need to visit Medscape's website.
Click here to view the activity or if you are logged in click on the "Complete Activity" button!
 
Please login or create an account to proceed.